Geneva Capital Management LLC Buys 7,958 Shares of Repligen Corporation (NASDAQ:RGEN)

Key Points

• Geneva Capital Management LLC increased its stake in Repligen Corporation by 5.9% during Q1, acquiring an additional 7,958 shares for a total of 143,543 shares worth approximately $18.26 million.
• Several hedge funds, including Price T Rowe Associates and Point72 Asset Management, have significantly increased their holdings in Repligen, indicating strong institutional interest in the company.
• Repligen's latest quarterly earnings report revealed a missed EPS expectation ($0.37 vs. $0.40) but a 14.8% year-over-year revenue growth, with revenues of $182.37 million.

Geneva Capital Management LLC raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 5.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,543 shares of the biotechnology company's stock after purchasing an additional 7,958 shares during the period. Geneva Capital Management LLC owned 0.26% of Repligen worth $18,264,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Argent Trust Co bought a new position in Repligen during the 1st quarter worth about $212,000. Bank of Nova Scotia bought a new position in Repligen during the first quarter worth about $2,149,000. PNC Financial Services Group Inc. increased its holdings in Repligen by 4.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,632 shares of the biotechnology company's stock valued at $462,000 after buying an additional 152 shares during the period. Blueshift Asset Management LLC bought a new position in Repligen in the first quarter valued at about $458,000. Finally, Commerce Bank increased its holdings in shares of Repligen by 7.5% during the first quarter. Commerce Bank now owns 1,899 shares of the biotechnology company's stock worth $242,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

RGEN has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. cut their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Evercore ISI lowered their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Wells Fargo & Company cut their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $169.45.

Repligen Stock Performance

NASDAQ:RGEN traded up $0.62 on Thursday, reaching $112.72. 401,018 shares of the company's stock were exchanged, compared to its average volume of 782,224. The stock has a fifty day simple moving average of $123.06 and a 200-day simple moving average of $135.30. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -452.16, a P/E/G ratio of 2.13 and a beta of 1.05. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. Repligen's quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.40 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.